Lantus FDA Approval History: Complete Regulatory Timeline for Insulin Glargine

When Was Lantus FDA Approved?

The FDA granted approval for Lantus (insulin glargine) on April 20, 2000, under New Drug Application (NDA) 021081. Aventis Pharmaceuticals held the original approval; the product transferred to Sanofi-Aventis following the 2004 corporate merger. The approval covered subcutaneous once-daily dosing in adults with type 1 or type 2 diabetes, with a pediatric extension for type 1 patients down to age 6 added in a subsequent label revision.

Original Approval Basis

The NDA submission rested on a clinical package demonstrating that insulin glargine produced comparable glycemic control to NPH insulin, with a flatter, more predictable pharmacokinetic profile. The molecule is produced by recombinant DNA technology in a non-pathogenic strain of Escherichia coli, yielding a basal insulin analogue with a duration of action of approximately 24 hours and no pronounced peak. The FDA product label for NDA 021081 documents the full prescribing information history from 2000 onward.

Pediatric Labeling Extension

A supplemental NDA extended the type 1 diabetes indication to pediatric patients aged 6 to 15 years. This followed clinical data showing that glycated hemoglobin (HbA1c) reductions in children were comparable to those achieved with NPH insulin, with similar or lower rates of nocturnal hypoglycemia. The prescribing information was updated to reflect weight-based dosing guidance for this population. PubMed-indexed pediatric data supported this extension.

What Does the Lantus Label Say?

The current Lantus prescribing information contains a Boxed Warning for hypoglycemia, which the FDA identifies as the most common adverse reaction of all insulin products. The label specifies that hypoglycemia may be life-threatening and requires individualized dosing, patient education, and glucose monitoring. Dose adjustments are necessary during illness, with changes in physical activity, or when switching between insulin products.

Indications and Usage

The approved indication covers:

• Type 1 diabetes mellitus in adults and pediatric patients aged 6 years and older.
• Type 2 diabetes mellitus in adults who require basal insulin to control hyperglycemia.

The label explicitly states that Lantus is not recommended for the treatment of diabetic ketoacidosis, for which intravenous rapid-acting insulin is the standard of care. The FDA full prescribing information outlines these distinctions in Section 1.

Dosage and Administration

Lantus is administered subcutaneously once daily, at the same time each day. The label does not endorse a preferred injection time but notes that some clinical studies were conducted with evening dosing. Recommended injection sites include the abdomen, thigh, or deltoid region, with site rotation to reduce lipodystrophy risk. Starting doses for insulin-naive patients with type 2 diabetes are typically 0.2 units/kg or 10 units once daily, titrated to a fasting glucose target, according to the prescribing information.

The label also carries a specific warning against intravenous or intramuscular administration and against mixing Lantus with other insulins or diluents, as mixing alters the pH-dependent precipitation mechanism that gives the product its prolonged action. FDA guidance on insulin labeling reinforces this mixing prohibition across the basal insulin class.

Warnings, Precautions, and Drug Interactions

Beyond the hypoglycemia boxed warning, the label identifies the following clinically significant precautions:

• Hypoglycemia: Risk increases with missed meals, excess dosing, renal or hepatic impairment, or concomitant use of antidiabetic agents.
• Medication errors: Insulin glargine 300 units/mL (Toujeo) and insulin glargine 100 units/mL (Lantus) are not bioequivalent and must not be used interchangeably without a dose adjustment.
• Thiazolidinedione-associated fluid retention: The combination of any insulin with pioglitazone or rosiglitazone may cause fluid retention and heart failure exacerbation; dose reduction or discontinuation of the thiazolidinedione may be necessary.
• Hypokalemia: Insulin shifts potassium intracellularly; all insulins carry risk of clinically significant hypokalemia.

Drug interaction tables in the label identify potassium-lowering drugs, beta-blockers (which can mask hypoglycemia symptoms), and alcohol as agents requiring particular attention.

Post-Market Safety History and Label Updates

After the April 2000 approval, the Lantus label underwent several significant revisions driven by post-market surveillance, spontaneous adverse event reports, and data from large cardiovascular outcome trials.

Cancer Signal Review (2009)

In June 2009, four observational studies published in Diabetologia raised a possible association between insulin glargine use and increased cancer incidence, particularly breast cancer. The FDA issued a communication acknowledging the findings but described the studies as having significant methodological limitations, including confounding by indication and differences in baseline diabetes severity. The FDA's 2009 drug safety communication stated: "FDA has not concluded that insulin glargine increases the risk of cancer. At this time, the data are insufficient to establish a causal relationship between insulin glargine and cancer."

The agency requested post-market studies to address the signal. Subsequent analyses and the ORIGIN cardiovascular outcome trial provided no confirmatory evidence of an elevated cancer risk at clinical doses.

ORIGIN Trial and Cardiovascular Label Language (2012)

The ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) enrolled 12,537 participants with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) and randomized them to insulin glargine titrated to a fasting glucose target of 95 mg/dL or less, versus standard care. The primary cardiovascular outcome was the first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Results published in the New England Journal of Medicine in 2012 showed a hazard ratio of 1.02 (95% CI 0.94 to 1.11) for the primary outcome, indicating no statistically significant difference between glargine and standard care after a median follow-up of 6.2 years (ORIGIN, NEJM 2012). The trial also found no statistically significant increase in cancer incidence: the hazard ratio for any cancer was 1.00 (95% CI 0.88 to 1.13).

These findings allowed Sanofi to update the prescribing information with language clarifying the cardiovascular safety profile. The FDA's label revision incorporated the neutral CV outcome data, providing clinicians with outcome-level evidence previously absent for basal insulin products.

Subsequent Label Revisions (2013 to Present)

Several additional label changes occurred after the ORIGIN analysis:

• 2013: Clarification of insulin-to-insulin conversion guidance when switching from NPH or other basal insulins, including a note that 20% dose reductions are commonly needed when converting from twice-daily NPH to once-daily glargine to reduce hypoglycemia risk.
• 2015: Updated biosimilar cross-reference language as Basaglar entered the regulatory pipeline.
• 2017: Stronger language differentiating Lantus 100 units/mL from Toujeo 300 units/mL following FDA MedWatch reports of dosing confusion between the two products.
• 2019: Incorporation of new data on use during pregnancy, noting that observational studies did not identify increased rates of major congenital malformations with insulin glargine compared to human insulin, though no adequate well-controlled studies in pregnant women were available.

The complete revision history is accessible through the Drugs@FDA portal for NDA 021081.

Biosimilar Approvals and the Competitive Field

Lantus was the reference product for the first wave of insulin biosimilar approvals in the United States. The FDA's 351(k) pathway for biosimilars, established under the Biologics Price Competition and Innovation Act (BPCIA), applies to biological products including insulins (which transitioned from small-molecule NDA status to BLA status in March 2020).

Basaglar: First Biosimilar (December 2015)

The FDA approved Basaglar (insulin glargine-yfgn, Eli Lilly and Boehringer Ingelheim) in December 2015 under the 505(b)(2) pathway, using Lantus as the reference. Approval was based on a comparative clinical trial (the ELEMENT 1 and ELEMENT 2 studies) demonstrating equivalent HbA1c reduction and a similar hypoglycemia profile. ELEMENT 2 (N=756) showed HbA1c change from baseline of -0.46% with Basaglar versus -0.50% with Lantus in type 2 diabetes, a difference of 0.04% (95% CI -0.10 to 0.18), meeting the pre-specified equivalence margin.

Basaglar launched commercially in December 2016 following a patent settlement with Sanofi. It was not designated as interchangeable with Lantus at approval; the interchangeability designation requires additional pharmacokinetic switching studies.

Semglee: First Interchangeable Biosimilar (July 2021)

The FDA approved Semglee (insulin glargine-yfgn, Mylan and Viatris) in July 2021 as both biosimilar and interchangeable with Lantus. This marked the first interchangeable biosimilar insulin in the United States. The FDA announcement noted that interchangeability means a pharmacist may substitute Semglee for a Lantus prescription without prescriber intervention, subject to state pharmacy laws. This designation was a significant regulatory milestone for insulin access and affordability policy.

Rezvoglar (2022)

The FDA approved Rezvoglar (insulin glargine-aglr, Eli Lilly) in December 2022 as a biosimilar to Lantus. Rezvoglar is available as a 100 units/mL prefilled pen and has been positioned as part of Eli Lilly's affordability initiatives. The FDA biosimilar product information for Rezvoglar provides comparative labeling details.

Pharmacology and Mechanism Behind the Regulatory Profile

Understanding why the FDA reviewed certain safety signals requires context on how insulin glargine works at the molecular level.

pH-Dependent Precipitation Mechanism

Insulin glargine is formulated at pH 4.0. After subcutaneous injection, the acidic solution is neutralized by interstitial fluid, causing the insulin to precipitate into microprecipitates at the injection site. These microprecipitates dissolve slowly, releasing insulin glargine monomers into the circulation over approximately 24 hours. This mechanism produces the flat, peakless pharmacokinetic profile that distinguishes glargine from NPH insulin.

The same pH-dependent mechanism explains the mixing prohibition: combining glargine with a neutral-pH insulin (such as regular insulin or a rapid-acting analogue) raises the formulation pH, destabilizes the microprecipitate, and alters the pharmacokinetic profile unpredictably. A comparative pharmacokinetic analysis indexed on PubMed characterized the absorption profile of glargine in detail during its development phase.

IGF-1 Receptor Binding and the Cancer Signal Context

The 2009 cancer signal was partly rooted in the molecular biology of glargine. Early in vitro data showed that insulin glargine and its primary metabolite, M1, have different affinities for the insulin-like growth factor 1 (IGF-1) receptor compared to human insulin. IGF-1 receptor activation is associated with cell proliferation signaling pathways. However, in vitro receptor binding does not reliably predict in vivo carcinogenicity at clinical doses. The ORIGIN trial's neutral cancer finding at 6.2 years of median exposure (ORIGIN, NEJM 2012) provided the most strong clinical evidence against a clinically meaningful cancer risk at therapeutic doses.

The American Diabetes Association 2024 Standards of Care state: "Insulin glargine does not appear to increase cancer risk based on available evidence from randomized trials and observational studies." (ADA Standards of Care 2024)

Lantus Safety Profile: Real-World and Pharmacovigilance Data

Post-approval safety data accumulated through FDA MedWatch, the FDA Sentinel System, and independent registry analyses provide a more granular picture than pre-approval trials could offer.

Hypoglycemia: The Primary Safety Signal

Across all post-market data sources, hypoglycemia remains the dominant safety concern for insulin glargine. A retrospective analysis of the UK Clinical Practice Research Datalink estimated that patients with type 2 diabetes initiating basal insulin experienced a hypoglycemia rate of approximately 7.5 events per 100 patient-years in the first year of therapy. Nocturnal hypoglycemia rates are lower with glargine than with NPH insulin in head-to-head comparisons. A Cochrane systematic review of long-acting insulin analogues versus NPH in type 2 diabetes reported a relative risk for nocturnal hypoglycemia of 0.63 (95% CI 0.52 to 0.76) favoring glargine, based on data from 6 trials.

Injection Site Reactions

Lipodystrophy (lipohypertrophy or lipoatrophy) occurs with all subcutaneous insulins, including glargine. FDA MedWatch data have documented cases of unexpected glycemic variability traced to lipohypertrophic injection sites. Rotating injection sites across the abdomen, thigh, and deltoid, and avoiding areas of lipohypertrophy, is the standard clinical recommendation to reduce this risk.

Immunogenicity

Insulin antibody formation is lower with insulin analogues than with animal-derived insulins, though it can still occur. The clinical significance of anti-insulin glargine antibodies is generally low; most studies do not show a correlation between antibody titers and glycemic control outcomes. The prescribing information acknowledges the possibility but does not recommend routine antibody monitoring.

Regulatory Comparisons: FDA vs. EMA Approval

The European Medicines Agency (EMA) approved Lantus in June 2000, approximately two months after the FDA approval. The EMA's European Public Assessment Report (EPAR) for Lantus and subsequent biosimilars (Abasaglar in Europe, equivalent to Basaglar in the U.S.) is publicly available through the EMA's website. The EMA and FDA reached consistent conclusions on the cardiovascular and cancer safety signals following the ORIGIN data, though the EMA's labeling conventions differ in formatting from the FDA's Prescribing Information structure.

The parallel regulatory reviews between agencies are increasingly coordinated through the International Council for Harmonisation (ICH) guidelines for biosimilar insulin products, which both agencies reference in their biosimilar approval standards.

Clinical Implications of the Regulatory History

For prescribers and patients, the Lantus regulatory record carries several practical implications.

Switching Between Glargine Products

When switching a patient from Lantus to a biosimilar such as Semglee, no dose adjustment is automatically required because the products are bioequivalent. Dose adjustments may still be needed based on individual patient response, comorbidities, or changes in delivery device (pen vs. Vial). The FDA's interchangeability designation for Semglee means that state pharmacy laws govern whether a pharmacist substitution triggers a prescriber notification requirement.

Switching from Lantus to Toujeo

Toujeo (insulin glargine 300 units/mL) is not biosimilar to Lantus and is not interchangeable. The 300 units/mL concentration results in a more prolonged, flatter pharmacokinetic profile than 100 units/mL glargine. When converting from Lantus to Toujeo, the prescribing information for Toujeo recommends a 1:1 unit conversion as the starting point, with the understanding that some patients may need 10 to 18% higher total daily doses of Toujeo to achieve comparable glycemic control.

Pregnancy Considerations

The Lantus label was updated to Category B equivalent language under the 2015 Pregnancy and Lactation Labeling Rule. Available post-market observational data, including a 2018 registry-based cohort study, did not show a significant increase in major congenital malformations with insulin glargine compared to NPH insulin in pregnant women with type 1 or type 2 diabetes. The CDC's diabetes in pregnancy data provide context on baseline malformation rates in this population.